Veraxa Biotech AG (VRXA)
| Market Cap | 155.55M -53.0% |
| Revenue (ttm) | 29,543 |
| Net Income | -84.01M |
| EPS | -5.80 |
| Shares Out | 141.41M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 114,458 |
| Open | 1.130 |
| Previous Close | 1.110 |
| Day's Range | 1.060 - 1.150 |
| 52-Week Range | 1.040 - 27.360 |
| Beta | 0.19 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About VRXA
Veraxa Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment. The company develops antibody-based therapeutics, including antibody-drug conjugates and bispecific antibody formats, and offers a proprietary technology platform for functional antibody screening and bioconjugation. Its product pipeline includes drug candidates such as ADCs and BITACs, with some in clinical development, and it provides partnership models for collaborative development from target identification to antibody and ADC creation.... [Read more]
News
Veraxa Biotech presents in vivo, in vitro data for BiTAC-ADC technology platform
Veraxa Biotech (VRXA) presented first in vivo proof-of-concept data and additional in vitro data validating its novel BiTAC-ADC technology platform at the 17th World ADC Congress in San Diego, Califor...
VERAXA Biotech Presents in vivo Proof-of-Concept Data for BiTAC®-ADC Technology at World ADC Congress
VERAXA Biotech presents first in vivo proof-of-concept for BiTAC®-ADC: tumor-selective activation with potent anti-tumor efficacy and improved safety.
Micro-Cap Stock Veraxa Biotech Is Down 96% This Year. Can Next-Gen Drug Testing Save It?
Veraxa is shifting away from animal testing to get drugs to market faster, calling it ‘not just a regulatory obligation, but a scientific opportunity.'
Veraxa Biotech to implement FDA-aligned NAMs across development programs
Veraxa Biotech (VRXA) provided an update on its strategy and progress to implement a suite of FDA aligned new approach methodologies, or NAMs, across its preclinical research and development programs,...
VERAXA Biotech Provides Overview on Implementation of FDA-Aligned Human-Relevant Models into R&D Strategy
Consistent Use of New Approach Methodologies (NAMs) to Potentially Accelerate BiTAC® Oncology Pipeline and Significantly Reduce Animal Testing Needs.
Veraxa Biotech appoints Raju Willener as CFO
Veraxa Biotech (VRXA) announced the appointment of Raju Willener as CFO, effective immediately. Willener will report to Christoph Antz, CEO and co-founder.
VERAXA Biotech Appoints Raju Willener as Chief Financial Officer
Zurich, Switzerland, Sept. 04, 2026 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA” or the “Company”), a leading developer of next-generation antibody-based cancer therapies, today annou...
Veraxa Biotech, Secarna announce initial results from AOC alliance
Veraxa Biotech (VRXA) and Secarna Pharmaceuticals announced initial results from their strategic research collaboration to develop next-generation antibody oligonucleotide conjugates for the treatment...
Veraxa Biotech AG Registration statement: Registration filing
Veraxa Biotech AG filed a registration statement on August 5, 2026, providing details about a securities offering with the SEC.
Veraxa Biotech AG Registration statement: Registration filing
Veraxa Biotech AG filed a registration statement on August 5, 2026, providing details about a securities offering with the SEC.
Veraxa Biotech AG Registration statement: Registration filing
Veraxa Biotech AG filed a registration statement on July 31, 2026, providing details about a securities offering with the SEC.
Veraxa Biotech AG Registration statement: Registration filing
Veraxa Biotech AG filed a registration statement on July 31, 2026, providing details about a securities offering with the SEC.
VERAXA Biotech Strengthens Patent Portfolio to Protect Core Technology Platforms and Product Candidates
ZURICH, SWITZERLAND, July 29, 2026 (GLOBE NEWSWIRE) -- VE RAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer therapies, today provided an update on its core patent ...
Veraxa Biotech advances VXA-222 following milestone in OmniAb pact
Veraxa Biotech (VRXA) announced the advancement of bispecific ADC program VXA-222, following successful achievement of a key technical milestone in its alliance with OmniAb (OABI). The program is movi...
VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAb
VERAXA Biotech's and OmniAb's bispecific ADC program VXA-222 advances into next phase at VERAXA following the achievement of a key technical milestone.
VERAXA Biotech Shareholders Approve All Proposals at Extraordinary General Meeting, Strengthening Strategic Flexibility for Future Growth
ZURICH, SWITZERLAND , July 24, 2026 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in the design and development of next-generation cancer therapeutics, held an Ext...
Veraxa Biotech appoints Christoph Erkel as chief scientific officer
Veraxa Biotech (VRXA) announced the appointment of Christoph Erkel as chief scientific officer, effective immediately. Christoph Erkel, previously VP of research and development at Veraxa Biotech, wil...
VERAXA Biotech Appoints Christoph Erkel as Chief Scientific Officer to Advance BiTAC® Technology Platforms and Portfolio
ZURICH, SWITZERLAND, July 23, 2026 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer therapies, today announced the appointment of Christoph ...
VERAXA Biotech Announces Regulatory Progress with its BiTAC®-TCE Development Plan
ZURICH, SWITZERLAND – July 20, 2026 – VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA), an emerging leader in designing novel cancer therapies, today announced that it has received Scientific Advice from the...
Veraxa Biotech announces BiTAC pipeline collaboration with Ardigen
Veraxa Biotech (VRXA) announced a collaboration with Ardigen to support Veraxa’s growing BiTAC pipeline of t cell engagers and antibody drug conjugates. The partnership with Ardigen will initially foc...
VERAXA Biotech to Launch AI-enabled Drug Discovery Collaboration with Ardigen to Support Growing BiTAC® Pipeline
ZURICH, SWITZERLAND – July 13, 2026 -- VE RAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer therapies, today announced a collaboration with Ardigen S.A., an AI-dri...
Veraxa CFO Torsten Burgermeister steps down, Carl von Halem named interim CFO
Veraxa Biotech (VRXA) announced the appointment of Carl von Halem as interim CFO. He succeeds Torsten Burgermeister. The company is currently in the final stages of discussions with a successor.
VERAXA Biotech AG Appoints Carl von Halem as Interim Chief Financial Officer and Successor to Torsten Bürgermeister
ZURICH, SWITZERLAND – July 10, 2026 -- VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer therapies, today announced the appointment of Carl von Halem as Interim ...
Veraxa Biotech provides pipeline and partnering strategy update
Veraxa Biotech (VRXA) provided a company and pipeline update, highlighting its strategic focus on its proprietary BiTAC platform. The company intends to channel the majority of its investments into it...
VERAXA Biotech Provides Business Update and Further Details on Partnering Strategy and Development Timelines
ZURICH, SWITZERLAND – July 6, 2026 -- VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer therapies, today provided a company and pipeline update. “In the first si...